Because T2DM is included in the cardio-renal metabolic syndrome, it is also important to emphasize the benefits of the novel antidiabetic non-insulin drugs from the large cardiovascular outcome trials (CVOT); specifically, a reduction in the major adverse cardiovascular events (MACE), including acute MI, stroke, CV mortality, all-cause mortality, and CV safety [28,29,30]. This evidence concerns the gene INS and stroke disorder.